Every 8-K that Sera Prognostics, Inc. (SERA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SERA filings page.
Sera Prognostics, Inc. (SERA) announced a planned chief financial officer transition. The board appointed Scott Gleason as Chief Financial Officer and Treasurer, effective August 31, 2026, under an employment agreement and standard officer indemnification. Gleason, age 47, brings approximately 25 years of experience across diagnostics, life sciences, healthcare finance, investor relations, and corporate strategy, including senior roles at Neogen, NX Prenatal, LarmorBio, OraSure Technologies, and Myriad Genetics.
Current CFO and Treasurer Austin Aerts will step down on August 31, 2026 as part of the planned succession and will enter a consulting role. Under a Consulting Agreement effective September 8, 2026, he will provide services for twelve months at $375 per hour, with his existing employee stock options and restricted stock units continuing to vest during the consulting term and vested options remaining exercisable for three months afterward.
Sera Prognostics, Inc. reported second quarter 2026 results and business updates. Revenue for the quarter was $30,000, up from $17,000 a year earlier, while total operating expenses were $10.0 million. Net loss was $9.1 million compared with $8.0 million in the prior-year quarter, reflecting higher selling, marketing and general and administrative spending to support commercialization.
The company ended the quarter with $80.3 million in cash, cash equivalents and available-for-sale securities and stated this is expected to fund operations through significant adoption and commercialization milestones through 2029. Highlights included launch of a fourth partnership program for the PreTRM® Test with a state-based initiative and national payer, new Illinois legislation mandating Medicaid coverage for proteomic tests assessing preterm birth risk, additional PRIME trial data and recognitions, progress toward European CE marking with pre-application activities expected in the third quarter and submission in the fourth quarter of 2026, and strengthened commercial leadership and board expertise.
Sera Prognostics appointed Mark Capone to its Board of Directors as a Class II director, effective July 1, 2026, with a term running until the 2029 annual meeting. He will also serve on the Compensation Committee.
Capone is a veteran healthcare executive with over 40 years of experience in diagnostics and life sciences, including a 17-year tenure at Myriad Genetics where he helped grow the business significantly. As a non-employee director, he will receive an initial equity award on July 10, 2026, equal to the lesser of a grant-date fair value of $167,072 (split roughly evenly between stock options and RSUs) or 150,000 option equivalents, plus ongoing cash fees under the existing director compensation policy.
After each annual meeting, he is eligible for additional equity of the lesser of $88,359 or 75,000 option equivalents, with RSUs and options vesting over one year. The Board determined he qualifies as an independent director under Nasdaq and SEC rules.
Sera Prognostics, Inc. held its 2026 annual stockholder meeting by live audio webcast. Of 38,190,966 Class A common shares eligible to vote as of April 13, 2026, 25,773,203 shares were represented, forming a 67.5% quorum.
Stockholders elected Kim Kamdar, Ph.D. and Sandra A. J. Lawrence as Class II directors to serve until the 2029 annual meeting, with Kamdar receiving 9,749,623 votes for and Lawrence 12,483,966 votes for, plus broker non-votes in each case. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 24,917,046 votes for and 856,113 against.
Sera Prognostics, Inc. reported a planned board transition, with director Jeff Elliott resigning effective June 4, 2026, coinciding with the company’s Annual Stockholders Meeting. His departure is described as not resulting from any disagreement over operations, policies or practices, and his current term was already set to expire at that meeting.
The board reduced its size to seven directors following his resignation and is in advanced discussions with highly qualified candidates to join, expecting to announce a new appointment in the near term. Elliott, who joined the board in March 2025, expressed continued confidence in Sera’s mission to improve maternal and neonatal health through its PreTRM Test and broader pregnancy diagnostics pipeline.
Sera Prognostics, Inc. reported first quarter 2026 results, showing it remains in an early commercial stage while emphasizing extended financial runway. Revenue was $14,000 versus $38,000 a year earlier, reflecting limited commercial adoption of its PreTRM test so far.
Total operating expenses were $9.4 million, with $3.0 million in research and development and $6.3 million in selling, general and administrative costs as the company invests in commercialization. Net loss was $8.4 million, or $0.17 per share, similar to the prior-year loss.
As of March 31, 2026, Sera held about $86.8 million in cash, cash equivalents and marketable securities and expects this to fund operations through 2029 after a business review that shifted spending from clinical work toward reimbursement-driven commercialization. The company highlighted new clinical evidence for its PreTRM test, growing clinician engagement, payer discussions across 15 states and progress toward CE marking in Europe.
Sera Prognostics, Inc. reported fourth quarter and full year 2025 results, highlighting a continued investment phase ahead of broader commercialization of its PreTRM pregnancy test. Fourth quarter 2025 revenue was $10,000, with a net loss of $7.9 million, while full year 2025 revenue was $81,000 and net loss was $31.9 million.
Total 2025 operating expenses were $36.6 million, with research and development of $13.2 million and selling, general and administrative expenses of $23.3 million. The company ended 2025 with $95.8 million in cash, cash equivalents and marketable securities, which it expects to fund operations through key commercial milestones into 2028.
Strategically, Sera emphasized the publication of the pivotal PRIME Study showing the PreTRM test reduced early preterm births and neonatal complications, expanding commercial discussions with payers across 13 U.S. states, progress toward European commercialization, and leadership additions to support its shift from clinical validation to commercial execution.
Sera Prognostics, Inc. filed a current report to note that it has posted a new investor presentation on its corporate website as of January 8, 2026. The presentation is included as Exhibit 99.1 to the report and is incorporated by reference for informational purposes. The company specifies that this material is being furnished under Regulation FD and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities filings.
Sera Prognostics, Inc. filed a current report to highlight a communication event rather than a financial update. On January 7, 2026, the company issued a press release announcing publication of the results of its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study in the Pregnancy Journal.
The newly published PRIME study results are scheduled to be discussed during a Jefferies-hosted fireside chat on January 9, 2026, at 8:30 am ET. The press release is furnished as Exhibit 99.1 and, along with the related disclosure under Item 7.01, is treated as "furnished" rather than "filed" for liability purposes under the Exchange Act.
Sera Prognostics, Inc. filed a current report to share that findings from its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study have been accepted for publication in a peer-reviewed journal. The company disclosed this information under a Regulation FD disclosure, indicating it was also announced in a press release dated November 24, 2025, furnished as an exhibit to the report.
Sera Prognostics, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025. The company disclosed the results and business highlights via a press release furnished as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.